

Scientific, Technical & Medical Investor Seminar

November 3, 2026

DISCLAIMER REGARDING FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results or outcomes of RELX PLC (together with its subsidiaries, "RELX", "we" or "our") to differ materially from those expressed in any forward-looking statement. We consider any statements that are not historical facts to be "forward-looking statements". The terms "outlook", "estimate", "forecast", "project", "plan", "intend", "expect", "should", "could", "will", "believe", "trends" and similar expressions may indicate a forward-looking statement. Important factors that could cause actual results or outcomes to differ materially from estimates or forecasts contained in the forward-looking statements include, among others: regulatory and other changes regarding the collection or use of personal data; changes in law and legal interpretation affecting our intellectual property rights and internet communications; current and future geopolitical, economic and market conditions; research integrity issues or changes in the payment model for our scientific, technical and medical research products; competitive factors in the industries in which we operate and demand for our products and services; our inability to realise the future anticipated benefits of acquisitions; compromises of our cybersecurity systems or other unauthorised access to our databases; changes in economic cycles, trading relations, communicable disease epidemics or pandemics, severe weather events, natural disasters and terrorism; failure of third parties to whom we have outsourced business activities; significant failure or interruption of our systems; our inability to retain high-quality employees and management or to develop capabilities in emerging technologies at an appropriate pace; changes in tax laws and uncertainty in their application; exchange rate fluctuations; adverse market conditions or downgrades to the credit ratings of our debt; changes in the market values of defined benefit pension scheme assets and in the market related assumptions used to value scheme liabilities; breaches of generally accepted ethical business standards or applicable laws; and other risks referenced from time to time in the filings of RELX PLC with the US Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except as may be required by law, we undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.

Overview and Strategy


Kumsal Bayazit
CEO




STM Investor Seminar Agenda


Overview and Strategy	Kumsal Bayazit, CEO	Slides 5-13
Primary Research	Gemma Hersh, SVP, Primary Research	Slides 14-22
Decision Support Tools overview	Kumsal Bayazit, CEO	Slides 23-39
• Research Solutions	Maxim Khan, SVP Product	
• Nursing Solutions	Paul Crockett, SVP Product	
Technology	Jill Luber, CTO	Slides 40-48
Key takeaways	Kumsal Bayazit, CEO	Slide 49
Q&A		


STM position within RELX
H1 2026






STM revenue by geography and by type
H1 2026







STM revenue by segment
H1 2026



We operate in long-term global growth industries: Research






- R&D investment drives innovation, economic growth, and solutions to societal challenges


- Consistent, long-term growth in number of researchers
- Technology advancements continue to improve researcher productivity

Consistent long-term growth

Values are for OECD + Key Countries, forecasts include stimulus additions from planned Government spending in USA, EU and Japan. Sources: OECD (March 2026), UNESCO (Feb 2021; used for historical data only), World Bank (Jul 2026), IMF (Nov 2025). Note: The OECD restates prior figures and forecasts as new information is made available to them; this can cause totals and growth rates to be different to previous reports.

We operate in long-term global growth industries: Health






- Aging population
- Longer and healthier lifespan
- Consistent, long-term growth in number of healthcare professionals

Consistent long-term growth

Values are for OECD + Key Countries. Sources: OECD (March 2026), World Bank (Jul 2026), IMF (Nov 2025), Fitch Solutions (BMI download: March 2026). Note: The OECD restates prior figures and forecasts as new information is made available to them; this can cause totals and growth rates to be different to previous reports.

We serve a wide range of customers



Research institutions and funders

- >10,000 academic and government institutions
- >95% of top 1,000[1] academic and government institutions
- >99% of Nobel Laureates in science since 2000

R&D intensive corporates

- >2,000 corporates
- >95% of top 100 biopharmaceutical companies[2]
- ~80% of top 100 R&D driven corporations[2]

Health

- >1,200 medical schools and >3,800 nursing institutions globally
- >5,500 healthcare institutions

1. 'Top' measured by volume of published research. 2. Top 100 by R&D spend. World2000 and Evaluate Pharma.

Strategic priorities

Expand customer value in Primary Research

- Continue to deliver industry-leading research quality, article volume, and user experience at a lower effective price


Deliver increasing customer value with our Decision Support tools

- Enhance value of existing analytics solutions and expand into new use cases by combining deep domain expertise, leading evidence-based scientific content, advanced analytics and evolving technology

Leverage global, modular technology platform to build segment-leading products and drive process innovation

- Continue to build technology agnostic and multi-model scalable technology platforms, to accelerate pace of product innovation, organisational speed and agility, and to drive efficiencies

Underlying revenue growth




- Improving long-term revenue growth trajectory by:
  - Continued high-quality volume growth in Primary Research
  - Increasing pace of product innovation in Decision Support

Objective: Continue on improving long-term growth trajectory

2024 and prior growth includes print & print-related

Underlying adjusted operating profit growth



- Improving long-term profit growth trajectory
- Manage cost growth through process innovation, agility and speed

Objective: Continue to manage profit growth ahead of revenue growth

2024 and prior growth includes print & print-related

Primary Research

Gemma Hersh
SVP, Primary Research

We help validate, improve and disseminate science

Researchers write up their research and seek the right journal for publishing it.

Editors drive the publication process by evaluating submissions, overseeing the review process and providing feedback to authors.

Peer reviewers are experts in their research field; they help validate the science and suggest improvements.

Industry-leading, scalable journal ecosystem



Validate that articles are sound science and a good fit to our journals

- **>3,000** journal brands
- **>4.6m** article submissions[1]
- **~6** authors per article
- **2+** peer reviewers per article

Help authors **improve their articles** and edit for **accuracy and completeness**

- **>37,000** editors
- **~105,000** editorial board members
- **>1.9m** reviewers
- **94%** of articles have content changes in peer review
- **95%** of articles have content changes in production

Drive **visibility, usability and global reach** on leading platforms


- **>800,000** articles published[1]
- **2.9bn** articles consumed[1,2]
- **>24m** articles archived

1. LTM to June 2026


2. Unique article views and downloads

Clear leader in quality

Article and citation share[1]



Share of articles per quality tier (FWCI[2])




1. Share of articles per publisher (published in 2021-2024) and share of citations (citations in 2021-24 in relation to articles published in 2021-2024)

2. Field-Weighted Citation Impact (FWCI) for articles published in 2021-2024. FWCI is the ratio of citations received for each article relative to the normalised, expected average of 1.The ratio for each article is normalised based on the expected number of citations by article type, subject field, and publication year

Source: Scopus data

Industry: Global published articles

Global industry published articles (millions)




- R&D spend growing across government, higher education & business sectors
- Number of researchers growing globally
- Artificial Intelligence accelerating scientific discovery and improving researcher productivity

Total published articles growing globally

Elsevier submissions: strong growth

Elsevier articles submissions (millions)




- Breadth of portfolio across disciplines and tiers
- Reputation for quality and high-impact journals
- Leverage technology to continue to improve user experience for authors, editors, reviewers

Strong growth in submissions

Elsevier published articles: strong growth

Elsevier published articles (millions)




- Expanding journals portfolio and global presence
- Article transfer service finds home for all appropriate articles
- Innovation in editorial tools and scalable processes grow output without compromising quality

Publishing higher volume of high-quality articles

Elsevier revenue per article: improving value

Elsevier submissions, publications, revenue and revenue per article[1]



Primary Research growth strategy:

- Submitted articles growing double digits
- Published articles growing mid-to-high single digits
- Elsevier Primary Research revenue growing below published articles

Increasing value per dollar spent

1. All values represent 3-year rolling averages for Primary Research articles (pay-to-read and pay-to-published) and revenue (in USD)

Creating measurable value for authors, editors and reviewers leveraging sophisticated analytics

Safeguard research integrity and trust

- Screening from submission to after publication
- Multiple detection signals: AI misuse, authorship, citations, paper mills and data fabrication
- Detection to resolution, with traceable decisions
- An arms race, as with fraud in other industries, leveraging Risk capabilities and know-how

Higher quality, faster process and better user experience

Live and scaling

- Streamlined submission process: faster, better-quality submission
- Online peer review process: higher transparency, less friction and faster decisions
- High author, reviewer and editor satisfaction
- Improved speed and acceptance rate
- Change management at scale

In testing

- AI editor tools to streamline the work and remove admin
- Agentic content enrichment process decreasing time from acceptance to publication
- Rolling out LeapSpace capabilities e.g. Claim Radar

Keeping **human judgement at the core,** underpinned by **deep domain expertise** and a global **community of subject matter experts**

Primary Research: key takeaways

- Segment growth continues to be driven by volume growth
- Elsevier's published articles growing faster than the industry
- We continue to increase customer value
- Our objective in Primary Research is to deliver continued gradual improvements in growth

Decision Support Tools

(Databases, Tools & Electronic Reference)

Kumsal Bayazit
CEO

We help customers solve complex use cases

Product Category	Research Solutions		Nursing Solutions	Medical Solutions and Other
	Manage & Evaluate Research	Conduct & Publish Research		
Example use cases	• Set funding priorities • Manage funding awards and assess outcomes • Build research teams • Manage faculty recruitment / progression	• Discover, synthesise and utilise scientific content • Identify research topics, find collaborators and funding • Write and publish manuscripts • Support R&D for drugs, materials and new product development • Support regulatory approval and compliance	• Student: build knowledge, apply skills, and assess exam readiness • Faculty: create course and assess student understanding • Practitioner: Support ongoing professional development and point of care	• Student: build knowledge, apply skills, and assess exam readiness • Faculty: create course and assess student understanding • Physician: Support professional development and point of care • Patient: Education and engagement
Users	• Grant officers • Academic leaders	• Academic researchers and students • Corporate scientists and engineers	• Nursing students • Nursing faculty • Practising nurses	• Medical students and faculty • Physicians, pharmacists and patients • Clinical operations teams
Buyers	• Universities and research institutes • Funding bodies and government agencies • R&D-intensive corporations	• Universities and research institutes • Funding bodies and government agencies • R&D-intensive corporations	• Nursing schools • Hospitals and health systems	• Medical schools • Hospitals and health systems • Pharmacies • Corporations

Expand our suite of high value solutions: Improve existing use cases, expand into new use cases, integrate where customers work

Four drivers of higher customer value improving revenue growth trajectory

- Increasing value of our existing high value tools
- Launching new high value products
- Building interoperable product suites
- Integrating into customer environments

The combination of one or more of these drivers improves customer value

Four key capabilities



1. Deep customer understanding and domain expertise

- Deep customer relationships
- Extensive industry experience
- Expert community of editors, editorial boards, peer reviewers and advisory boards
- Human oversight across curation, integrity checks and evaluation of AI outputs




2. Leading content and data

- Proprietary scientific journal and medical portfolio of highest quality
- Licenced and curated databases, rights-cleared and comprehensive
- Domain depth, e.g. engineering, chemistry, life-sciences
- Multimedia health content across continuum of care



3. Sophisticated linking and analytics

- Semantic enrichment through taxonomies and ontologies for scientific reasoning
- Derived data in knowledge graphs with billions of linked data points
- Decades of history, expert-curated and continuously updated



4. Advanced technology in global platforms

- Global, modular, flexible architecture: build once, reuse everywhere
- Technology agnostic and multi-model
- Private and secure, customer data not used to train frontier models
- Evidence-based verifiable AI outputs, transparent by design, consistent and traceable

Research Solutions

Maxim Khan
Senior Vice President, Product


Support all stakeholders across the research ecosystem

Decision Support

	Manage & Evaluate Research			Conduct & Publish Research		
Illustrative research journey	**Define and execute funding strategy**	**Define and execute research strategy**	**Manage faculty & research processes**	**Conduct research**	**Publish research**	**Apply research**
What	Help funders and policy-makers **set funding priorities, manage awards and assess funding impact**	Help academic leaders **shape research strategy, build research teams, assess funding outcomes and impact** versus peers, and **manage faculty recruitment and progression**		Help researchers **discover and access content**, **identify topics and funding opportunities**, **find collaborators** and select **appropriate journal for submissions**	Help academic researchers **publish research articles**, preprints and datasets, **conduct peer reviews**, and perform editorial duties	Help **corporate** researchers with **drug and new product development**
Who	Funders / government	Research offices and academic leaders		Academic / Corporate Researchers		
Key Elsevier products	• Analytical services • SciVal	• Scopus • Data Monitor • Funding Institutional	• Pure • Interfolio • Digital Commons	• Scopus • ScienceDirect • Reaxys • Engineering Village • Embase	• Mendeley • Editorial Manager • SSRN • Knovel • SciBite	• PharmaPendium

LeapSpace

LeapSpace: Integrated AI-enabled research workspace



- **Launched in January 2026** as an evolution from ScienceDirect AI launched in March 2025; continued rapid expansion of capabilities since launch


Key value drivers:

- **Improves outcomes** for tasks across the full research journey such as ideation, exploration, planning and collaboration in one seamless workspace
- **Grounded in comprehensive trusted content** including Scopus, Elsevier's proprietary full text content, licensed content from select publishers, funding data and user data
- **Evidence-based and verifiable outputs** which support creativity, curiosity, and critical thinking through transparency and explainability with Trust Cards
- **Agentic capabilities** including deep research, Claim Radar, Writing Coach and funding database

Content and algorithm standards are guided by the LeapSpace Advisory Board, an independent, external group of international academics

1. Scopus data coverage, 1.9K publishers licensed for full-text 2. LeapSpace draws on ~25m full-text covering approximately 56% of Scopus last-five-years citation share

LeapSpace demo



LeapSpace: Very positive customer feedback and rapid usage growth

- **Very positive customer feedback on value:** Better outcomes, greater efficiency, trust and control
- **Go-to-market approach:** Subscriptions to Academic and Government institutions and Corporate customers
- **Rapid usage growth:** Growth in activated users, monthly active users

Nursing Solutions

Paul Crockett,
Senior Vice President, Product

Support the nursing journey from education to practice

Illustrative Nursing Journey



Aspiring Healthcare Professional



Build Knowledge



Apply and Practise



Assess and Review



Clinical Practice

∞ *Non-linear, continuous learning cycle across Build Knowledge, Apply and Practise, Assess and Review and Clinical Practice*

	Build Knowledge	Apply and Practise	Assess and Review	Clinical Practice
What	Help educators facilitate **student learning and mastery**; help students build foundational knowledge	Help educators develop student clinical readiness; help **students apply clinical judgement skills**	Help educators **assess student licensure exam readiness**; help students prepare for licensure exam success	Help hospitals **transition new graduates into practice**; help practising nurses **deliver evidence-based care and with continuing education**
Who	Educators and Nursing Students			Nursing Practitioners
Key Elsevier products	• Sherpath AI • ClinicalKey Student • Osmosis • Complete Anatomy	• Shadow Health	• HESI	• ClinicalKey Nursing AI • Care Planning • Clinical Skills

Nursing education: Higher customer value through connected enterprise offering

Trusted content

Curated healthcare education content continually updated by **experienced nurse practitioners and educators**

15k Sherpath lessons

500k Elsevier Adaptive Quizzing Questions

100k Elsevier HESI Assessment Questions

2k+ Whiteboard-style learning videos, patient simulation models and assignments

+

AI-enabled teaching

Modular offering can be connected to provide opportunity for **end-to-end learning support**

Build knowledge: Sherpath AI

Conversational tutor based on Elsevier trusted content; provides answers and builds lesson and study plans

Apply Clinical Judgment: Shadow Health

Voice-driven patient simulations using speech-to-text and language processing


Assess & Review: HESI

Personalised learning plans and practice tests that remediate each learner's gaps

+

Predictive analytics

Dashboards show faculty and deans each student's likelihood of passing the required NCLEX[1] exam, so they can intervene early




+ our education solutions integrate with customers' learning management systems

1. National Council Licensure Examination - the standardised, computer-adaptive licensure exam required to obtain a nursing licence in the United States and Canada

Nursing education: Enabling positive student outcomes

Build Knowledge

Students who used **Sherpath and Elsevier Adaptive Quizzing scored 15% higher on practice exams** than students who did not[1]



Assess & Review


98% of students scoring the HESI benchmark of 850+ on their HESI practice exam, **pass their licensure exam** on their first attempt[3]

Apply Clinical Judgment

74% of students who use Shadow Health simulations increase their clinical judgment skills (explicitly measured on the licensure exam)[2]

1. Study of c.600 students. 2. Study of c.2,000 students. 3. Study of c.1,750 students

Nursing education: Sherpath AI is our core AI-enabled interactive learning assistant



Sherpath AI


Launched in Oct 2024

Combines Elsevier's trusted content with advanced generative AI to support students and educators

- **Trusted Content**
- **Interactive Dialogue**
- **Verifiable Citations**
- **Personalised Context**
- **Multimedia Content**
- **Responsible AI**

- Independent learning with trustworthy resources
- Anytime/Anywhere Q&A
- Personalised Content Generation
- Expands faculty bandwidth

Nursing education: Sherpath AI Demo



Nursing education: Enterprise level offering driving customer value expansion

Case study: A leading US university

2025 revenue
$0.2M

2027F revenue
$1.7M

Limited purchasing of Elsevier nursing products at the course level

Purchasing the full suite of Elsevier nursing flagship products at the programme level


No Elsevier contract: school purchasing on a seminar-by-seminar basis

Multi-year Elsevier contract: school decided to sign a three-year contract

Greater customer value through expanded relationship

Successful user outcomes from using a combination of our solutions drive **greater customer value and penetration** of our nursing courses

Spend per student **more than doubles** in our highest package tier




Decision Support: key takeaways

- Growth in global research drives increased demand for trusted evidence-based tools
- We continue to add greater value in our Decision Support tools by improving existing use cases, expanding into new use cases, and embedding where customers work
- Our objective in Decision Support is to continue to translate higher customer value into continued gradual improvements in growth with our increasing pace of product innovation
- Innovation is enabled through the combination of our deep customer and domain expertise, leading content and data, sophisticated linking and analytics, and advanced technology platforms

Technology

Jill Luber
Chief Technology Officer

RELX technology



Global Scale

- $2bn RELX annual technology spend
- More than 12,000 technologists at RELX
- 15+ years of experience with big data and AI/ML
- Technology agnostic
- Leverage approaches across RELX

STM Technology: Extracting context and insights at scale

SOURCE CONTENT

- Journals, books
- Patents
- Policy documents
- Clinical trial data
- Drug databases

Structure, enrich and validate content into trusted entities

DERIVED DATA

72M · 11M · 433M · 9M · 83K · 76M · 54K · 374M · 51K

Connect entities and relationships with full semantic context


CONNECTED CONTEXT



+ user context

Reason over connected context plus user context to generate insights and actions

INTELLIGENCE



STM product examples

- LeapSpace
- Scopus AI
- Sherpath AI
- ClinicalKey AI
- SciVal
- Reaxys
- Osmosis AI

HUMAN EXPERTISE, GOVERNANCE & OVERSIGHT

AI **AI SUPPORT FOR CURATION, VALIDATION & ENHANCEMENTS (continuous feedback loops)**

Structured and unstructured content

- >109m publication records, from >48k sources; >179m patents; >3m preprints; >9m grants; c.8m policy doc links
- >54k drug database records; clinical trial data; clinical guidelines

Connected context, grounded in domain expertise

- Entity extraction, tagging and linking to structure unstructured content at scale
- Expert-informed taxonomies and ontologies to normalise, disambiguate and contextualise entities
- Semantic relationships across disciplines and domains to connect concepts, evidence and knowledge

Intelligence & Agents


- Specialised agents for discovery, synthesis, analysis and decision support
- Agent orchestration to coordinate tasks, tools and knowledge across workflows
- Human-guided intelligence with validation, transparency and feedback built in

Content, data and analytics to deliver better outcomes

	Leading scientific and medical content and data		+ Sophisticated linking and analytics		+ Context layer	=
	Proprietary	**Licensed and curated**	**Derived data**	**Semantic layer**	**Connected context**	
Definition	Elsevier published content: journals, society guidelines, clinical overviews, monographs, multimedia content	3rd party publisher content, open access, patents, grants, policy, drug information, preprints	Enriched data and knowledge graphs: citations, authors, diseases, chemical reactions, substances, drugs & symptoms	Domain-specific taxonomies, millions of concepts across research, biology, chemistry and health	Semantic relationships across disciplines, connecting concepts, evidence and knowledge	**AI outputs that are more accurate, relevant and verifiable**
Value	High quality; proprietary	Breadth and depth: 300 disciplines, domain depth	Analytic layer: Structured, connected, normalised and disambiguated data	Semantic layer: Domain-specific scientific concepts understanding	Connected context to generate domain specific insights and actions	
Our strengths	• Editorial and production integrity • Peer review and domain network • Research integrity	• Thousands of different sources • Curated • Rights management, version of record	• Billions of data points • Longitudinal data: expert-curated and continuously updated • Structured networks and knowledge graphs	• 50+ domain taxonomies • Millions of concepts • Deep data science and domain expertise	• Multi-model architecture, technology agnostic and built to absorb change • Human validation, transparency and feedback built in	

Reliable, dependable evidence-based layer

Example: chemistry and biomedicine



Consistent and repeatable output: one scientific task, delivered the same way every time

Combination of deep data science and domain expertise to optimise outputs

Example

Customer question:

'Does gene X regulate protein Y expression in human cell lines?'

STAGE 1

Understand

- **Intent**
  What the user actually wants
- **Concepts**
  Named entities and relations
- **Constraints**
  Time, domain, language

STAGE 2

Retrieve

Lexical	*exact terms*
Semantic	*meaning vectors*
Structured	*citation graph, ontology*

ACROSS

Text	Abstracts	Tables
Equations	Figures	


STAGE 3

Evidence-based, repeatable answer

- **Citations**
  claim → source mapping
- **Explainable**
  why this evidence won
- **Repeatable**
  same query, same answer

Technology agnostic, multi-model approaches drive quality, speed, and cost

Example: Model selection process



Process innovation and agility

Continuous process innovation, now accelerated by AI, to manage cost growth below revenue growth

Select examples

Technology	• Spec-driven development enhances code quality and shortens development lifecycles • Reusable, modular platforms shorten launch times across products
Operations	• Automated, reusable content pipelines process growing volumes at lower cost • AI-assisted evaluation of product outputs ensures accuracy and quality
Customer Support	• AI agents improve response speed and consistency • Automated case routing and prioritisation improve operational efficiency
Sales & Marketing	• Technology-assisted analysis of customer conversations surfaces insights • Channel and audience analysis identifies optimal approach to connect with customers

Summary: Elsevier's technology platform enables agile innovation at scale



Faster innovation and development

Build once, reuse everywhere - new AI features ship in days, not quarters




Evidence-based answers

Precision AI, trust cards and evaluation keep outputs more accurate, traceable, and consistent



Technology flexibility

Multi-Model approach - no lock-in; we switch to the most appropriate models as the market evolves



Cost efficiency

AI-assisted development, **pre-computed content** and **prompt optimisation** reduce the cost to build, run and support our products

Key takeaways

- We operate in large, global segments with attractive structural long-term growth drivers
- We have segment-leading positions helping our customers with complex and critical use cases
- We deliver customer value through the combination of domain expertise, leading scientific content, sophisticated linking and analytics and advanced technology platforms
- Our objectives are to continue to deliver higher customer value, continue on our improving long-term revenue growth trajectory, and manage profit growth above revenue growth

Q&A